Preview

Medical Genetics

Advanced search
Open Access Open Access  Restricted Access Subscription Access

Population genetic epidemiology of cystic fibrosis in the Republic of Bashkortostan

https://doi.org/10.25557/2073-7998.2025.09.29-31

Abstract

Introduction. Сystic fibrosis (CF) is characterized by pronounced genetic heterogeneity and, in this regard, clinical variability, occurs in all countries of the world, but there are pronounced population differences in its frequency with decreasing gradient of distribution from North to South and from West to East of Eurasia.

Aim: the study of regional clinical, genetic and epidemiologic features of CF for the development of optimal algorithms for diagnosis and treatment of the disease is relevant.

Patients and Methods. The molecular genetic study included 1403 people, including family members, control and population samples, observed from 1998 to 2023 in the Republican Medical and Genetic Center (Ufa). Clinical and laboratory and molecular genetic methods of research, bioinformatic processing of NGS sequencing results were used.

Results. Genetic heterogeneity of CF by spectrum and frequencies of pathogenic changes in CFTR gene in ethnic groups of RB was revealed; mutations 3849+10kbC->T, p.[G509D;E217G] are specific for patients of Tatar and Bashkir ethnicity, 394delTT and p.[S466X;R1070Q] – for Tatars.

Conclusion. Introduction of molecular genetic technologies, allowed to develop an effective algorithm of DNA-diagnosis of the disease.

About the Authors

G. R. Ayupova
Bashkir State Medical University
Russian Federation

Guzel R. Ayupova

3, Lenina st., Ufa, 450008



E. G. Komova
Company Vector-Best
Russian Federation

PO box 492, Novosibirsk, 630117



E. F. Agletdinov
Company Vector-Best
Russian Federation

PO box 492, Novosibirsk, 630117



R. I. Khusainova
Bashkir State Medical University
Russian Federation

3, Lenina st., Ufa, 450008



References

1. Zvereff V.V., Faruki H., Edwards M., et al. Cystic fibrosis carrier screening in a North American population. Genetics in Medicine. 2014;16(7): 539–546.

2. Mogayzel P.J., Naureckas E.T., Robinson K.A. Cystic fibrosis pulmonary guidelines. Chronic medications for maintenance of lung health. The American Journal of Respiratory and Critical Care Medicine. 2013;187(7): 680-689.

3. Mukovistsidoz. Izdaniye 2-ye., pererabotannoye i dopolnennoye (pod redaktsiyey N.YU. Kashirskoy, N.I. Kapranova i Ye.I. Kondrat’yevoy) [Cystic fibrosis. 2nd edition, revised and supplemented (edited by N.Yu. Kashirskaya, N.I. Kapranov and E.I. Kondratieva)]. M.: ID «MEDPRAKTIKA-M» [M.: Publishing house «MEDPRAKTIKA-M»], 2021, 680 p. (In Russ.)

4. Registr patsiyentov s mukovistsidozom v Rossiyskoy Federatsii. 2022 god. / pod red. Voronkovoy A.YU., Amelinoy Ye.L., Kashirskoy N.YU. i dr. [Registry of patients with cystic fibrosis in the Russian Federation. 2022. / edited by Voronkova A.Yu., Amelina E.L., Kashirskaya N.Yu. et al.]. Moscow: ID «MEDPRAKTIKA-M», 2024, 68 p. (In Russ.)


Review

For citations:


Ayupova G.R., Komova E.G., Agletdinov E.F., Khusainova R.I. Population genetic epidemiology of cystic fibrosis in the Republic of Bashkortostan. Medical Genetics. 2025;24(9):29-31. (In Russ.) https://doi.org/10.25557/2073-7998.2025.09.29-31

Views: 6


ISSN 2073-7998 (Print)